Kite EU B.V. - Tufsteen 1a

4.2/5 based on 5 reviews

About Kite EU B.V.

Our Story

A Singular Focus on Cell Therapy

Founded in 2009 as a pioneer in cell therapy research, Kite’s leadership position in the immuno-oncology space was solidified with our research and development agreement with the National Cancer Institute in 2012 and when our commercial manufacturing site opened in El Segundo in 2016. Since our acquisition by biopharma leader Gilead Sciences in October 2017, our combined strength has accelerated the advancement of our pipeline, including the launch of YESCARTA® (axicabtagene ciloleucel) and TECARTUS® (brexucabtagene autoleucel), and has expanded the impact of our strategic partnerships.

As an independent operating company since 2019, we prioritize innovative R&D with the full resources, capabilities, and trust of Gilead. As a vital part of Gilead — a founding member of the Foundation for the NIH’s Partnership for Accelerating Cancer Therapies — we are devoted to advancing the understanding of cell therapy as a transformational treatment option for cancer. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer.

For more on Kite’s acquisition by Gilead Sciences in 2017, read the press release.

See Our Pipeline

Contact Kite EU B.V.

Address :

Tufsteen 1a, 2132 NT Hoofddorp, Netherlands

Postal code : 2132
Website : https://www.kitepharma.com/
Categories :
City : Hoofddorp

Tufsteen 1a, 2132 NT Hoofddorp, Netherlands
l
linda van veen on Google

K
Kees van Beelen on Google

m
michiel vd kolk on Google

b
bomma reddy kesava harshini on Google

K
Karin de Zwart on Google

Lange wachttijden
Long waiting times

Write some of your reviews for the company Kite EU B.V.

Your reviews will be very helpful to other customers in finding and evaluating information

Rating *
Your review *

(Minimum 30 characters)

Your name *